Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections.

Karol Majewski, Elżbieta Kozłowska, Paulina Żelechowska, Ewa Brzezińska-Błaszczyk
Author Information
  1. Karol Majewski: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland.
  2. Elżbieta Kozłowska: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland.
  3. Paulina Żelechowska: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland.
  4. Ewa Brzezińska-Błaszczyk: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland.

Abstract

Nowadays, data indicate that antimicrobial peptides play an important role in immunological defense. Human cathelicidin LL-37 possesses a broad spectrum of antimicrobial properties against Gram-positive and Gram-negative bacteria, and is thereby an important component of defense mechanisms within the respiratory tract. In this study, we determined the LL-37 serum level in patients with pneumonia caused by different bacteria species in comparison with healthy subjects. Twenty-two patients with pneumonia caused by coccal Gram-positive bacteria (I), 16 patients with pneumonia caused by Haemophilus influenzae (II), 29 patients with pneumonia caused by members of the Enterobacteriaceae (III), 13 patients caused by non-fermenting Gram-negative bacteria (IV), and 30 healthy controls were enrolled in the study. Serum LL-37 concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The mean LL-37 concentration in pneumonia patients was significantly higher in group I (p = 0.0032), group II (p = 0.0022), and group III (p = 0.019), and significantly lower in group IV (p = 0.000004) as compared with healthy volunteers. Our data suggest that LL-37 plays an important role in defense mechanisms during pneumonia. The reduced level of this peptide in subjects with pneumonia caused by opportunistic bacteria may reflect weakened immune system reactivity in these patients.

Keywords

References

  1. J Exp Med. 2000 Oct 2;192(7):1069-74 [PMID: 11015447]
  2. Blood. 2000 Nov 1;96(9):3086-93 [PMID: 11049988]
  3. Am J Respir Crit Care Med. 2002 Apr 1;165(7):992-5 [PMID: 11934727]
  4. J Immunol. 2004 Jan 15;172(2):1146-56 [PMID: 14707090]
  5. J Cyst Fibros. 2004 Mar;3(1):45-50 [PMID: 15463886]
  6. Pulm Pharmacol Ther. 2005;18(5):321-7 [PMID: 15939310]
  7. Cell Microbiol. 2005 Jul;7(7):1009-17 [PMID: 15953032]
  8. J Immunol. 2006 Mar 1;176(5):3044-52 [PMID: 16493063]
  9. Int Arch Allergy Immunol. 2006;140(2):103-12 [PMID: 16557028]
  10. Scand J Immunol. 2006 Jun;63(6):410-9 [PMID: 16764694]
  11. J Leukoc Biol. 2006 Sep;80(3):509-20 [PMID: 16793910]
  12. J Infect Dis. 2007 Nov 1;196(9):1425-30 [PMID: 17922409]
  13. Eur Respir J. 2008 Sep;32(3):670-7 [PMID: 18508823]
  14. J Transl Med. 2009 Apr 23;7:28 [PMID: 19389235]
  15. J Periodontol. 2009 Jun;80(6):969-76 [PMID: 19485828]
  16. Cell Host Microbe. 2009 Sep 17;6(3):231-43 [PMID: 19748465]
  17. J Leukoc Biol. 2010 Jan;87(1):79-92 [PMID: 19808939]
  18. Innate Immun. 2010 Jun;16(3):151-9 [PMID: 20418263]
  19. J Immunol. 2010 Aug 1;185(3):1442-9 [PMID: 20610648]
  20. Acta Trop. 2011 Jan;117(1):56-9 [PMID: 20887706]
  21. J Exp Med. 2010 Dec 20;207(13):2921-30 [PMID: 21115688]
  22. Hum Immunol. 2011 Aug;72(8):656-62 [PMID: 21539878]
  23. J Dermatol Sci. 2012 Jan;65(1):19-26 [PMID: 22047630]
  24. Blood. 2012 Nov 1;120(18):3699-707 [PMID: 22927244]
  25. Cell Immunol. 2012 Nov;280(1):22-35 [PMID: 23246832]
  26. Microbes Infect. 2013 May;15(5):342-6 [PMID: 23328115]
  27. Arch Oral Biol. 2013 Aug;58(8):930-4 [PMID: 23778112]
  28. Antimicrob Agents Chemother. 2013 Oct;57(10):4707-16 [PMID: 23856776]
  29. J Immunol. 2013 Nov 15;191(10):4895-901 [PMID: 24185823]
  30. Int J Tuberc Lung Dis. 2014 Jun;18(6):671-5 [PMID: 24903937]
  31. BMC Pediatr. 2014 Sep 25;14:238 [PMID: 25252824]
  32. Clin Infect Dis. 2015 Jan 15;60(2):177-87 [PMID: 25301213]
  33. J Matern Fetal Neonatal Med. 2015;28(18):2197-200 [PMID: 25354286]
  34. Exp Ther Med. 2015 Jan;9(1):11-16 [PMID: 25452769]
  35. Cell Immunol. 2015 Feb;293(2):67-73 [PMID: 25577339]
  36. Clin Rheumatol. 2015 Apr;34(4):795-8 [PMID: 25597616]
  37. Clin Respir J. 2017 Mar;11(2):243-247 [PMID: 26073571]
  38. Clin Invest Med. 2017 Feb 19;40(1):E34-E39 [PMID: 28218580]

Word Cloud

Created with Highcharts 10.0.0patientspneumoniaLL-37causedbacteriaantimicrobialdefensegroupp=0importantcathelicidinhealthydatapeptidesroleGram-positiveGram-negativemechanismsstudylevelsubjectsIIIIIIVSerumconcentrationsignificantlypeptideimmunesystemNowadaysindicateplayimmunologicalHumanpossessesbroadspectrumpropertiestherebycomponentwithinrespiratorytractdeterminedserumdifferentspeciescomparisonTwenty-twococcal16Haemophilusinfluenzae29membersEnterobacteriaceae13non-fermenting30controlsenrolledmeasuredusingenzyme-linkedimmunosorbentassayELISAmeanhigher00320022019lower000004comparedvolunteerssuggestplaysreducedopportunisticmayreflectweakenedreactivityconcentrationsbacteriallunginfectionshost

Similar Articles

Cited By